Pancreatic Cancer Research

ResearcherZhejiang Chinese Medical UniversityNo recent work listed

Yunfeng Shan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4811-8932; OpenAlex author ID A5014345054. Sources: OpenAlex.

Their work

Papers
13 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
32
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 3 papers · 2020: 2 papers · 2021: 4 papers

Papers 13

  1. Study of the Mechanism by Which Curcumin Cooperates with Sestrin2 to Inhibit the Growth of Pancreatic Cancer. Co-author DOI 10.1155/2021/7362233↗
  2. Inhibition of JAK2/STAT3 signaling pathway by panaxadiol limits the progression of pancreatic cancer. Last author DOI 10.18632/aging.203575↗
  3. The isoflavone puerarin exerts anti-tumor activity in pancreatic ductal adenocarcinoma by suppressing mTOR-mediated glucose metabolism. Co-author DOI 10.18632/aging.203725↗
  4. Dipeptidyl Peptidase-4 modulates Long-chain Acyl-CoA synthetase 4 to Promote Lipid Peroxidation and Regulate Ferroptosis in Pancreatic Cancer Co-author DOI 10.21203/rs.3.rs-173980/v1↗
  5. Identification of a competing endogenous RNA network associated with prognosis of pancreatic adenocarcinoma. Co-author DOI 10.1186/s12935-020-01243-6↗
  6. Correction to: Identification of a competing endogenous RNA network associated with prognosis of pancreatic adenocarcinoma. Co-author DOI 10.1186/s12935-020-01381-x↗
  7. LncRNA H19/miR-194/PFTK1 axis modulates the cell proliferation and migration of pancreatic cancer. Co-author DOI 10.1002/jcb.27669↗
  8. The role of lncRNA MSC-AS1/miR-29b-3p axis-mediated CDK14 modulation in pancreatic cancer proliferation and Gemcitabine-induced apoptosis. Co-author DOI 10.1080/15384047.2018.1529121↗
  9. Restoration of miRNA-148a in pancreatic cancer reduces invasion and metastasis by inhibiting the Wnt/β-catenin signaling pathway via downregulating maternally … Co-author DOI 10.3892/etm.2018.7026↗
  10. High Rab11-FIP4 expression predicts poor prognosis and exhibits tumor promotion in pancreatic cancer. Co-author DOI 10.3892/ijo.2016.3828↗
  11. Latexin exhibits tumor-suppressor potential in pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/or.2015.4353↗
  12. Effect of NK4 transduction in bone marrow-derived mesenchymal stem cells on biological characteristics of pancreatic cancer cells. Co-author DOI 10.3390/ijms15033729↗
  13. Experimental studies on treatment of pancreatic cancer with double-regulated duplicative adenovirus AdTPHre-hEndo carrying human endostatin gene. Co-author DOI 10.1016/j.pan.2013.05.012↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qiyu Zhang · 5 shared papers, 2013–2019 · strength 0.41
  2. Yunpeng Sun · 4 shared papers, 2014–2019 · strength 0.36
  3. Haotian Fu · 2 shared papers, 2021 · strength 0.30
  4. Hangcheng Guo · 2 shared papers, 2021 · strength 0.29
  5. Huanhuan Wu · 3 shared papers, 2014–2019 · strength 0.26
  6. Wanqing Weng · 2 shared papers, 2020 · strength 0.23
  7. Weiguo Huang · 2 shared papers, 2020 · strength 0.23
  8. Keqing Shi · 2 shared papers, 2020 · strength 0.23
  9. Zhuo Lin · 2 shared papers, 2020 · strength 0.23
  10. Qiandong Zhu · 2 shared papers, 2019 · strength 0.21
  11. Ni Xie · 1 shared paper, 2021 · strength 0.16
  12. Xuhui Fan · 1 shared paper, 2021 · strength 0.16
  13. Mengtao Zhou · 2 shared papers, 2014–2019 · strength 0.14
  14. Hongwei Sun · 1 shared paper, 2021 · strength 0.14
  15. Fubiao Ni · 1 shared paper, 2021 · strength 0.14
  16. Ding Li · 1 shared paper, 2021 · strength 0.14
  17. Shengjie Dai · 1 shared paper, 2021 · strength 0.14
  18. Yanyi Xiao · 1 shared paper, 2021 · strength 0.13
  19. Xiangyang Lin · 1 shared paper, 2021 · strength 0.13
  20. Hengyue Zhu · 1 shared paper, 2021 · strength 0.13
  21. Yangyang Guo · 1 shared paper, 2021 · strength 0.13
  22. Yongheng Bai · 1 shared paper, 2021 · strength 0.13
  23. Yun He · 2 shared papers, 2016–2017 · strength 0.12
  24. Zhanxiong Xue · 2 shared papers, 2016–2017 · strength 0.12
  25. Zhenzhai Cai · 2 shared papers, 2016–2017 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.